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Abstract: Lurasidone is a new second-generation antipsychotic approved in October 2010 by the 
Food and Drug Administration for the treatment of schizophrenia. Like other second-generation 
antipsychotics, lurasidone is a powerful antagonist of D2 dopamine and 5HT2A serotonin recep-
tors, but differs from the other second-generation antipsychotics in its action profile for certain 
receptors. Lurasidone is the second-generation antipsychotic with the greatest affinity for 5HT7 
receptors and has a high affinity for 5HT1A serotonin receptors, compatible with favorable effects 
on cognitive function and an antidepressant action. By contrast, lurasidone has a low affinity 
for α1 and α2C-adrenergic and 5HT2C serotonin receptors, and no affinity for histaminergic H1 or 
muscarinic M1 receptors, suggesting a better tolerability profile than the other second-generation 
antipsychotics. Lurasidone has demonstrated its efficacy in several short-term trials in acute 
schizophrenia, promptly and significantly reducing total Positive and Negative Syndrome Scale 
and Brief Psychiatric Rating Scale scores compared with placebo. Several long-term studies 
are in progress to assess its efficacy in the maintenance treatment of schizophrenic patients. The 
efficacy of lurasidone with regard to cognitive functions and depressive symptoms seems good, 
but requires further work. Lurasidone differs from the other second-generation antipsychotics 
by having a good tolerability profile, in particular for cardiometabolic tolerability. However, it 
seems to have a significant although moderate link with the occurrence of akathisia, extrapyra-
midal symptoms, and hyperprolactinemia at the start of treatment. This tolerance profile greatly 
broadens the scope of second-generation antipsychotics and so supports the view of some authors 
that the term “second-generation antipsychotic” is now outdated. Other therapeutic perspectives 
of lurasidone are assessed here, in particular bipolar depression.
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Management issues in schizophrenia
Schizophrenia is a serious chronic mental illness that appears in late adolescence or 
early adulthood, and affects about 1% of the world’s population.1 It is a heterogeneous 
condition characterized by positive and negative symptoms, and is often associated 
with cognitive disorders and symptoms of depression.
Pharmacological treatment is based essentially on antipsychotics. These drugs are 
central to care because they offer the only efficacious treatment for most of the symp-
toms. They allow both treatment of acute phases and the prevention of relapses.
Clozapine, introduced into the US in 1988, differed from classical neuroleptics not 
only in its greater efficacy but also, more importantly, by having markedly reduced neu-
rological effects.2 With this compound as leader, the atypical antipsychotics appeared at 
the end of the 1990s. However, atypicalness is a catch-all classification that is extremely Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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difficult to exploit operationally. The atypical antipsychotics 
form a heterogeneous group that have a pharmacodynamic 
action on neurotransmission that is different from that of the 
neuroleptics, with involvement of other neurotransmission 
systems, few or no induced extrapyramidal effects, and stron-
ger activity on negative schizophrenic symptoms.3 This very 
loose definition prompted a new terminology, ie, the terms 
“first-generation” and “second-generation” antipsychotics, 
which have been in use since 2004.
The second-generation antipsychotics are recommended 
in various guidelines as first-line treatment in view of their 
better neurological tolerability, and their greater efficacy 
on negative, cognitive, and depressive symptoms.4–7 They 
include the chemical entities amisulpride, aripiprazole, 
asenapine, clozapine, iloperidone, olanzapine, paliperi-
done, quetiapine, risperidone, sertindole, ziprasidone, and 
zotepine.
The superiority of second-generation antipsychotics 
over first-generation antipsychotics has been the subject of 
much debate, based on several meta-analyses published since 
2000. Some authors are not convinced of the superiority 
of second-generation antipsychotics and point to the poor 
methodological quality of the comparative trials in terms 
of evaluation criteria, dropouts, and choice and dose of 
comparator.8,9 A more recent meta-analysis singled out four 
second-generation antipsychotics that displayed greater over-
all efficacy compared with first-generation antipsychotics, 
namely clozapine, amisulpride, risperidone, and olanzapine. 
The other second-generation antipsychotics were no more 
efficacious than the older first-generation antipsychotics, 
even for negative symptoms.10
This difference in efficacy among the second-generation 
antipsychotics was confirmed in a meta-analysis of head-
to-head comparisons of second-generation antipsychotics. 
Olanzapine was found to be more efficacious than 
aripiprazole, quetiapine, risperidone, and ziprasidone, and of 
similar efficacy to amisulpride and clozapine.11 This difference 
among second-generation antipsychotics showed up mainly in 
the Positive and Negative Syndrome scale (PANSS) positive 
symptom subscores, and was small in the PANSS negative 
symptom subscores. CATIE (Clinical Antipsychotic Trials in 
Intervention Effectiveness) and CUtLASS (Cost Utility of 
the Latest Antipsychotic Drugs in Schizophrenia Study) gave 
similar results, except that clozapine stood apart from both 
first-generation antipsychotics and other second-generation 
antipsychotics.12,13
Concerning tolerability, whereas second-generation antip-
sychotics induced much weaker neurological side effects, 
they induced metabolic (weight gain, hyperglycemia, and 
dyslipidemia) and cardiac side effects (QT prolongation) 
requiring regular monitoring. Differences were also found 
among the second-generation antipsychotics. Although 
inducing fewer extrapyramidal effects compared with first-
generation antipsychotics, risperidone was associated with 
greater use of antiparkinsonian medication than clozapine, 
olanzapine, quetiapine, and ziprasidone.14 Also, concerning 
metabolic side effects, olanzapine and clozapine produced 
more weight gain than all the other second-generation 
antipsychotics, and olanzapine produced a higher rise in cho-
lesterol than aripiprazole, risperidone, and ziprasidone.15
Overall, these recent data confirm that second-generation 
antipsychotics are not a homogeneous group, that each 
second-generation antipsychotic possesses distinct phar-
macodynamic properties, and that consequently any new 
member may be of therapeutic interest. Lurasidone is a 
second-generation antipsychotic that was approved by the 
Food and Drug Administration (FDA) in October 2010 for 
the treatment of schizophrenia. Here we present the data 
available for this new agent concerning its pharmacological 
properties, efficacy, and tolerability in schizophrenic patients, 
and show the position of lurisadone with respect to the other 
second-generation antipsychotics.
Data sources
A literature search using the keywords “lurasidone” and 
“schizophrenia” was undertaken using the databases PubMed 
and EMBASE to find all the relevant studies published in 
English. Additional references were identified from http://
www.fda.gov and http://clinicaltrials.gov.16 Data were also 
collected from product user information.17 Searches were last 
updated on March 12, 2011.
Pharmacology and drug 
interactions
Pharmacological profile
Lurasidone is a benzoisothiazol derivative (SM-13496; 
(3aR,4S,7R,7aS)-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl) 
piperazin-1-ylmethyl] cyclohexylmethyl] hexahydro-4, 
7-methano-2H-isoindole-1,3-dione hydrochloride).
Like the other second-generation antipsychotics, lurasi-
done is a powerful antagonist of the dopamine D2 and sero-
tonin 5HT2A receptors, with a strong affinity for the 5HT2A 
receptor (Ki = 0.470–0.357 nM) and very high selectivity 
for the D2 receptor (Ki = 0.329–0.994 nM) 264, 16, and 30 
times greater, respectively, compared with D1, D3, and D4 
receptors.16 In a preliminary trial using positron emission Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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tomodensitometry in 21 healthy subjects, it was shown that 
the degree of occupation of D2 receptors at lurasidone dosages 
of 10, 20, 40, 60, and 80 mg ranged from 41.3% to 43.3%, 
51% to 54.8%, 63.1% to 67.5%, 77.4% to 84.3%, and 72.9% 
to 78.9%, respectively. An antipsychotic response, for which 
an occupation of 60%–80% of the receptors is required, could 
thus be expected from 40 mg/day.18
Lurasidone differs from other second-generation 
antipsychotics in its action profile for certain receptors. In vitro 
studies have shown that lurasidone is the second-generation 
antipsychotic that shows the greatest affinity for 5HT7 
receptors (Ki = 0.495–2.10 nM) and a high affinity for 5HT1A 
receptors.16,19 5HT7 receptors are abundant in the thalamic 
and hypothalamic regions involved in the regulation of sleep, 
and in the cortical areas and the regions of the hippocampus 
and raphe nuclei involved in memory and mood regulation.20,21 
Therefore, via these two receptors, lurasidone should have 
favorable effects on memory and cognitive functions, together 
with an antidepressive and anxiolytic action.22
In contrast with its high affinity for the 5HT7 and 5HT1A 
receptors, lurasidone has a moderate affinity for α2C-
adrenergic receptors, a very weak affinity for α1-adrenergic 
and serotonin 5HT2C receptors, and no affinity for histamin-
ergic H1 or muscarinic M1 receptors.16,19 Through its action 
on these different receptors, lurasidone should have a better 
tolerability profile than the other antipsychotics, in particular 
less risk of orthostatic hypertension (α2C and α1 receptors), 
less weight gain (H1 and 5HT2C receptors), less sedative effect 
(H1 and M1 receptors) and fewer anticholinergic effects (M1 
receptors).18
In vivo studies in animal models have shown that, com-
pared with other antipsychotic drugs, lurasidone carries a low 
risk for extrapyramidal symptoms or central nervous system 
depressive effects (motor coordination, muscle relaxation, 
anesthesia potentiation, bradykinesia, and catalepsy).19
Pharmacokinetics
Lurasidone is rapidly absorbed after oral administra-
tion, reaching peak concentrations (Tmax) in 1–3 hours.17 
Absorption is dose-dependent. For dosages in the range of 
20–160 mg/day, the area under the curve (AUC) and peak 
concentration (Cmax) increase linearly with the absorbed 
dose.17 Absorption is apparently favored by eating, as could 
be observed for ziprazidone. About 9%–19% of the dose 
administered is absorbed with no associated food intake, 
whereas AUC and Cmax are increased three-fold when at least 
350 calories of food is ingested concomitantly. Eating has 
no effect on Tmax.17
Steady-state is reached within seven days. For a lurasidone 
dose of 40 mg, a distribution volume estimated at 6173 L 
and a clearance of 3902 mL/min have been reported.17 The 
mean elimination half-life in trials including healthy subjects 
given a single dose of 100 mg/day was 12.2–18.3 hours, 
reaching 36 hours after nine days. The mean half-life in 
schizophrenic patients with single doses of 120–160 mg/day 
was 28.8–37.4 hours.18
The lurasidone molecule binds very strongly to 
plasma proteins (99.8%), in particular to albumin and 
α1-glycoprotein.23 Lurasidone is metabolized in the liver, 
principally by the cytochrome P450 (CYP) isoenzyme, 
CYP3A4, into three active and two inactive metabolites. 
The main active metabolite, ID-14283, an exohydroxy 
metabolite, is rapidly detected in the serum, with a Cmax value 
equal to 26% of the starting material. It has a comparable 
pharmacological profile, but a shorter life (7.48–10 hours) 
than lurasidone. The other two metabolites, ID-14326 and 
ID-11614, are present at extremely low levels of 3% and 
1%, respectively.18
Lurasidone crosses the placental barrier.16 Approximately 
89% is excreted in urine and stools. After administration of 
[14C]-lurasidone, 80% of the radioactivity was found in stools 
and 9% in urine.17
Cmax and AUC values increased in patients with mild, 
moderate, or severe renal and hepatic insufficiency, suggest-
ing that dosages should be adapted in these subjects.17 There 
seems to be no impact of race or age on the pharmacokinetics. 
Blood assays carried out in psychotic patients aged 65–85 
years taking lurasidone 20 mg/day showed concentrations 
identical to those in young subjects.17
Drug interactions
Because of hepatic metabolism of lurasidone by CYP3A4, 
there is a risk of drug interaction if lurasidone is taken 
concomitantly with inhibitors or inducers of this enzyme 
(diltiazem, ketoconazole, or erythromycin).17,18,23 Because 
lurasidone is not metabolized by CYP2D6, coprescription 
with inhibitors of CYP2D6, such as fluoxetine, paroxetine, 
and quinidine, needs no dosage adaptation. Lurasidone is 
not a substrate for P glycoprotein. No drug interactions have 
been observed when lurasidone is coprescribed with P gly-
coprotein substrates such as digoxin, or CYP3A4 substrates 
such as midazolam, oral contraceptives, or lithium.17,18 The 
high plasma protein-binding power of lurasidone, especially 
towards albumin and α1-glycoprotein, should be taken into 
account to avert certain drug interactions, in particular in 
undernourished subjects or the elderly.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Efficacy in schizophrenia
The efficacy of lurasidone in acute schizophrenia was 
assessed in eight trials (Table 1). Six short-term (six-week) 
randomized, double-blind, placebo-controlled trials (of 
which three used an active comparator, ie, haloperidol, 
olanzapine, or quetiapine) in acute schizophrenia, a short-
term (three-week) randomized, double-blind controlled trial 
(versus ziprasidone) in stable outpatients with schizophrenia 
or schizoaffective disorder, and a short-term (eight-week) 
randomized, double-blind dose-response study in inpatients 
and outpatients with schizophrenia.
The primary efficacy endpoint in all the trials was the 
mean change in PANSS or Brief Psychiatric Rating Scale 
(BPRS) total score from baseline to endpoint. Secondary 
endpoints included changes in Clinical Global Impression 
of Severity (CGI-S) and PANSS subscale scores. One study 
evaluated cognitive efficacy with a subset of the MATRICS 
Consensus Cognitive Battery (MCCB) and Schizophrenia 
Cognition Rating Scale.24
Placebo-controlled trials (except for one failed trial) 
demonstrated antipsychotic efficacy in all primary and 
secondary efficacy measures in favor of lurasidone 80 mg/
day. With the exception of two trials (one failed trial and 
D1050229), efficacy was found at lurasidone doses of 40, 
120, and 160 mg/day.
A pooled analysis based on five PANSS factor scores 
(positive, negative, disorganized thought, hostility, and 
depression/anxiety) was performed from four short-
term, double-blind, placebo-controlled trials (D1050006, 
D1050196, D1050229, and D1050231).25 Despite the inclu-
sion of a trial that did not find lurasidone to be efficacious 
at 40 or 120 mg/day, pooled data found lurasidone to be 
significantly better than placebo in improving all five PANSS 
factor scores. At week 6, changed scores and effect sizes were 
significant compared with placebo among patients treated 
with lurasidone at 40 mg, 80 mg, and 120 mg (Table 2).
Significant improvement in the different scores (BPRS, 
PANSS, and CGI-S) was observed by days 3–7 for the 
80–160 mg/day doses.16,26,27 In a study of stable patients, 
lurasidone 120 mg/day had an efficacy comparable with 
that of ziprasidone 160 mg/day, but with an earlier onset of 
improvement in PANSS total score (by day 7).28 These trials 
suggest an early onset of treatment effect for lurasidone.
Trial results did not suggest any additional benefit of 
lurasidone 120 mg/day over 40 mg/day or 80 mg/day (based 
on observed mean differences from placebo).16 Pooled analy-
sis found the treatment effect of lurasidone to be consistent 
across the dosage range, with no clear superiority of the 
highest lurasidone dose.25 No dose-response relationship for 
lurasidone was found.
A dose-response study of lurasidone 20, 40, and 80 mg/
day found that the 40 mg/day and 80 mg/day doses were 
associated with significant improvements from baseline on 
the PANSS and BPRS, and were significantly better than 
20 mg/day.29 The starting dose of lurasidone recommended 
by the FDA is 40 mg once daily, and the maximum dose is 
80 mg once daily.
The receptor binding profile of lurasidone, with high 
affinity for 5HT7, 5HT1A, and α2C receptors, and negligible 
affinity for muscarinic M1 and histaminic H1 receptors, was 
associated with a potential effect on cognitive function in 
schizophrenia.19 Data from placebo-controlled studies dem-
onstrated a significant improvement in the PANSS cognitive 
symptoms subscale (including conceptual disorganization, 
poor attention, and difficulty in abstract thinking).27 However, 
this subscale has not demonstrated a close correlation with 
performance-based cognitive tests.30
The cognitive effect of lurasidone was evaluated in 
comparison with ziprasidone in a short-term, randomized, 
double-blind trial. The outcome measures used were a 
performance-based cognitive assessment battery with most 
of the tests coming from the MCCB and an interviewer-rated 
measure of cognitive functioning, ie, the Schizophrenia Cog-
nition Rating Scale. There were no between-group treatment 
differences in these ratings, but lurasidone demonstrated 
significant within-group improvement from baseline on the 
MCCB composite score (P = 0.026) and on the Schizophrenia 
Cognition Rating Scale (P , 0.001), unlike ziprasidone. The 
very short duration of this trial, using a high dose of lurasi-
done (120 mg/day) and the use of an incomplete battery of 
tests set some limits to this study, which now requires further 
work to evaluate the cognitive effects of lurasidone.
Secondary analysis of one trial evaluated the efficacy of 
lurasidone in patients with schizophrenia who were experiencing 
clinically significant depressive symptoms (Montgomery-  Åsberg 
Depression Rating Scale [MADRS] . 12).31 Lurasidone-treated 
patients had significantly improved mean MADRS scores in the 
total sample (P = 0.026) and in the subgroup with MADRS . 12 
(P = 0.04) compared with placebo (last observation carried for-
ward). This trial is the only one to provide information on the 
efficacy of lurasidone in the treatment of depressive symptoms 
associated with schizophrenia. Double-blind Phase III trials 
are ongoing to confirm this potential benefit in schizophrenic 
patients with depressive symptoms.
The long-term efficacy of lurasidone in schizophrenia is 
being assessed from the extension phases of the short-term Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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trials and a six-month open-label extension trial evaluating the 
efficacy of lurasidone for the treatment of schizophrenia in sub-
jects switched from other antipsychotic agents. Only data from 
Sunovion Pharmaceuticals have reported the maintenance of 
clinical effect in lurasidone-treated patients for up to eight months 
(6.5 months extension) in the PEARL (Program to Evaluate the 
Antipsychotic Response to Lurasidone) 2 extension trial.32
Safety and tolerability
The safety assessment is based on data from over 2600 human 
subjects exposed to lurasidone (in Phase I, II, and III studies) 
with almost 500 patients exposed for more than six months and 
225 for more than one year.16 These data were assessed in the 
short-term trials already described and their long-term extension 
phases (Table 1). The first results of the PEARL safety trial over 
12 months were also included.33,34 Additional information is 
provided in the product monograph.17 The dose range examined 
in the Phase II and III trials was 20–120 mg/day (doses up to 
600 mg/day were evaluated in Phase I trials).
Common adverse events
Safety data based on pooled analyses from five short-term, 
placebo-controlled studies included 1004 lurasidone-treated 
patients and 455 placebo-treated patients.16,17,35 The most com-
mon adverse reactions (incidence $ 5% and at least twice the 
rate of placebo) in patients receiving lurasidone were akathisia 
(15%), nausea (12%), sedation (12%), somnolence (11%), 
parkinsonism (11%), insomnia (8%), agitation (6%), anxiety 
(6%), and dystonia (5%). Apparent dose-related adverse reac-
tions were akathisia and somnolence. Other common adverse 
events did not appear to be dose-related.
The long-term, risperidone-controlled trial substantiated 
the favorable profile of lurasidone, with a significantly lower 
incidence of somnolence, constipation, and weight increase 
(Table 3).33,34 This trial also suggested that akathisia, nausea, and 
vomiting may occur more frequently with lurasidone than with 
risperidone. Similar results were observed in a short-term, quetia-
pine-controlled trial.34 The short-term, ziprasidone-controlled trial 
found a statistically significant difference only in sedation.28
Table 3 Common adverse events for lurasidone versus active comparator28,33,34
Adverse  
event (%)
Short-term trials Long-term trials
D1050254 (3 weeks) D1050233 PEARL 3 (6 weeks) D1050237 (12 months)
Lurasidone  
120 mg/day
Ziprasidone 
160 mg/day
Lurasidone  
80 mg/day
Lurasidone 
160 mg/day
Quetiapine  
600 mg/day
Placebo Lurasidone 
40–120 mg/day
Risperidone 
2–6 mg/day
Akathisia 3.3 6.6 8 9 2 1 14.3 7.9
Nausea 7.3 4.6 8 6.6 3.4 3.3 16.7 10.9
vomiting 8 4 – – – – 10 3.3
Parkinsonism – – 5.6 6.6 3.4 0 4.3 5.4
Somnolence 6.7 9.9 4 6.6 13.4 0.8 13.6 17.8
Sedation 4.7 11.3 – – – – – –
insomnia 10.7 9.3 – – – – – –
Headache 6.7 4.6 – – – – – –
Dizziness 2.7 6.6 4.8 5.8 13.4 1.7 – –
Dry mouth – – 1.6 1.7 7.6 0.8 – –
Constipation – – 2.4 0.8 6.7 2.5 1.9 6.9
weight gain – – 0.8 1.7 6.7 0.8 9.3 19.8
Table 2 Results of a pooled analysis based on a five-factor model of schizophrenia25
Five PANSS  
factor scores
Lurasidone 40 mg/day Lurasidone 80 mg/day Lurasidone 120 mg/day
Change from  
baseline
P Effect  
size
Change from 
baseline
P Effect  
size
Change from  
baseline
P Effect 
size
Positive factor -7.92 ,0.001 0.35 -8.48 ,0.001 0.47 -8.25 ,0.001 0.42
Negative factor -5.59 ,0.001 0.41 -4.96 0.02 0.25 -5.21 0.002 0.31
Disorganized thought -4.86 ,0.001 0.40 -5.10 ,0.001 0.47 -5.22 ,0.001 0.50
Hostility -2.33 ,0.013 0.25 -2.58 0.002 0.33 -2.87 ,0.001 0.44
Depression/anxiety -3.14 0.002 0.31 -3.23 0.002 0.35 -3.01 0.012 0.26
Notes: Five PANSS factor scores were analysed using MMRM analysis. Adjusted effect sizes were calculated from an ANCOvA analysis (LOCF endpoint) as the between-
treatment group difference in least squares mean change scores divided by the pooled standard deviation of the change scores. Reprinted from Schizophrenia Research, 117, 
Loebel A, Cucchiaro J, Silva R, Ogasa M, Severs J, Marder SR, Efficacy of lurasidone in schizophrenia: Results of a pooled analysis based on a 5-factor model of schizophrenia, 
267, 2010, with permission from elsevier.
Abbreviations: ANCOvA, analysis of covariance; LOCF, last observation carried forward; MMRM, mixed-effect model repeated measure; PANSS, Positive and Negative 
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extrapyramidal symptoms, akathisia,  
and dyskinesias
Data provided by clinical trials were assessed on the 
  Simpson Angus Rating Scale for extrapyramidal symp-
toms, the Barnes Akathisia Scale for akathisia, and the 
Abnormal Involuntary Movement Scale for dyskinesias. 
In the short-term, fixed-dose, placebo-controlled trials for 
schizophrenia, treatment-emergent extrapyramidal side 
effects (excluding akathisia and restlessness) were observed 
in 14.7% of lurasidone-treated patients compared with 5.1% 
of placebo-treated patients.16,17 Akathisia was observed in 
15% of lurasidone-treated patients compared with 3.3% 
of placebo-treated patients. The incidence of dystonia 
for lurasidone-treated patients was 4.7% versus 0.7% for 
placebo-treated patients.
The mean change from baseline for lurasidone-treated 
patients was comparable with placebo-treated patients for 
extrapyramidal symptoms and dyskinesias, and was very 
close to placebo-treated patients for akathisia (lurasidone 0.2, 
placebo 0.0). The percentage of patients who shifted from 
normal to abnormal was greater in lurasidone-treated patients 
versus placebo for the Barnes Akathisia Scale (lurasidone 
16%, placebo 7.6%) and the Simpson Angus Rating Scale 
(lurasidone 5.3%, placebo 2.5%). Only akathisia appeared to 
be dose-related, but the greatest incidence of extrapyramidal 
side effect (including dystonia) occurred with the highest 
dose of lurasidone (120 mg/day). Akathisia is a common 
neurological adverse event with lurasidone, and is the most 
often reported side effect. Reported extrapyramidal side 
effects amounted to 22% and reported dystonia to 7% for 
patients treated with lurasidone doses of 120 mg daily. Long-
term treatment with antipsychotic drugs, especially at high 
dosages, is associated with the risk of tardive   dyskinesia. Data 
on the potential risk for tardive dyskinesia are still lacking, 
because of the limited information available from long-term 
clinical trials.
Metabolic side effects
Glucose metabolism
Pooled data from short-term, placebo-controlled studies 
showed a mean increase in fasting glucose of 1.4 mg/dL in 
the lurasidone group compared with a 0.6 mg/dL increase in 
the placebo group.16,17,35 There was no dose-response relation-
ship in the lurasidone group (Table 4). Changes in fasting 
glucose (mean from baseline and proportion of patients with 
shifts to $126 mg/dL) in lurasidone-treated patients were not 
statistically different from placebo-treated patients.
The uncontrolled longer-term trials (primarily open-label 
extension studies) reported a mean change in glucose of 
+1.6 mg/dL at week 24 (n = 186), +0.3 mg/dL at week 36 
(n = 236), and +1.2 mg/dL at week 52 (n = 244).17
In trials with an active comparator, a similar change in 
glucose was reported between lurasidone and ziprasidone 
(+4.7 versus +4.8 mg/dL).28 In pooled short-term trial analy-
sis, the median changes in glucose associated with lurasidone 
was unchanged (0.0), increased for olanzapine and haloperi-
dol (+4.0 and +2.0, respectively), and for placebo remained 
essentially unchanged (+1.0).16 In a longer-term safety trial, 
the median change from baseline in glucose observed was 
significantly different (P = 0.001) in favor of lurasidone, with 
a mean decrease of -0.5 mg/dL versus a mean increase of 
3.0 mg/dL for risperidone.33,34
Dyslipidemia
In short-term trials, mean increases were not observed for 
total cholesterol, low-density lipoprotein cholesterol, or 
triglyceride indices in the lurasidone group (Table 4).16,17,35 
Changes in fasting cholesterol and triglycerides (mean 
Table 4 Metabolic effects of lurasidone from short-term trials16,17
Placebo Lurasidone
20 mg/day 40 mg/day 80 mg/day 120 mg/day
Glucose
  Mean change from baseline (mg/dL) -0.7 -0.6 2.5 -0.9 2.5
 $ 126 mg/dL (%) 8.6 11.7 14.3 10.0 10.0
Total cholesterol
  Mean change from baseline (mg/dL) -8.5 -12.3 -9.4 -9.8 -3.8
 $ 240 mg/dL (%) 6.6 13.8 7.3 6.9 3.8
Triglycerides
  Mean change from baseline (mg/dL) -15.7 -29.1 -6.2 -14.2 -3.1
 $ 200 m g/dL (%) 12.5 14.3 14.0 8.7 10.5
weight
  Mean change from baseline (kg) 0.26 -0.15 0.67 1.14 0.68Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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from baseline and proportion of patients with shifts) in 
lurasidone-treated patients were not significantly different 
from placebo-treated patients.
The uncontrolled longer-term studies (primarily open-
label extension studies) reported no increase in mean change 
of total cholesterol and triglycerides.17 Lurasidone was asso-
ciated with a mean change in total cholesterol and triglycer-
ides (mg/dL) of -4.2 (n = 186) and -13.6 (n = 187) at week 
24, -1.9 (n = 238) and -3.5 (n = 238) at week 36, and -3.6 
(n = 243) and -6.5 (n = 243) at week 52, respectively.
In active comparator-controlled studies, treatment with 
lurasidone versus ziprasidone was associated with a greater 
reduction in triglycerides (-2.6 versus +22.4 mg/dL) and 
similar endpoint reduction in total cholesterol (-6.4 versus 
-4.4 mg/dL).28 In pooled analysis of the short-term studies, 
the median endpoint change in the lurasidone, haloperidol, 
and placebo groups decreased for total cholesterol and 
triglycerides, (-8.0, -8.0, -10 mg/dL and -5.0, -3.0 and 
-7.0 mg/dL, respectively) and in the olanzapine group 
increased significantly more (+9.0 and +25.0 mg/dL).16 In the 
PEARL 3 trial, triglyceride levels on lurasidone decreased in 
a similar fashion to that on placebo (placebo -9.0, lurasidone 
80 mg/day -2.0 and lurasidone 160 mg/day -9.0 mg/dL), 
compared with quetiapine, which increased triglyceride lev-
els (+8.0 mg/dL).32,34 In a long-term safety trial, the median 
change from baseline for lipid variables decreased similarly 
in lurasidone and risperidone groups.33,34
weight gain
Pooled data analysis from the short-term trials showed a mean 
increase in weight of 0.75 kg in the lurasidone group and of 
0.26 kg in the placebo group.16,17 The proportion of patients 
with a weight increase $ 7% was 5.6% for lurasidone-treated 
patients and 4% for placebo-treated patients. The weight gain 
did not appear to be related to lurasidone dose. The greatest 
weight gain was 1.14 kg and occurred with the middle dose 
of lurasidone (80 mg/day, Table 4).
The uncontrolled longer-term studies reported no increase 
in weight. Lurasidone was associated with a mean change in 
weight of -0.38 kg (n = 531) at week 24, -0.47 kg (n = 303) 
at week 36, and -0.71 kg (n = 244) at week 52.17
In trials with active comparators, the median endpoint 
change in weight at week 3 was similar for lurasidone and 
ziprasidone (-0.65 kg versus -0.35 kg, respectively).28 In 
pooled short-term trial analysis, weight gain $ 7% in the 
lurasidone, haloperidol, and placebo groups was similar 
(5.6%, 4.2%, and 4%, respectively) and much more fre-
quent in the olanzapine group (34.4%).16 In the PEARL 3 
trial, weight gain with lurasidone and placebo was similar   
(placebo +0.1 kg, lurasidone +0.6 kg) compared with quetia-
pine, which caused more weight gain (+2.1 kg).32,34
A long-term safety trial reported a mean change in weight 
at month 12 of -0.9 kg in the lurasidone group and +2.6 kg 
in the risperidone group. Unlike risperidone, which increased 
weight continuously over the 12 months, lurasidone did not 
change patient weight from the third month.33,34
Hyperprolactinemia
In short-term trials, the only significant difference found in 
the lurasidone group compared with the placebo group was 
the mean change from baseline in prolactin.16,17 Pooled data 
analysis from these trials showed a mean change from base-
line in prolactin levels of 1.1 ng/mL for lurasidone-treated 
patients and -0.6 ng/mL for placebo-treated patients. The 
increase in prolactin concentrations was dose-dependent 
and slightly greater in female patients. The greatest prolactin 
level occurred for the highest dose of lurasidone (120 mg/
day) and in women (6.7 ng/mL).
Conversely, the uncontrolled longer-term trials (primar-
ily open-label extensions) reported no increase in prolactin 
concentrations.17 Lurasidone was associated with a median 
change in prolactin of -1.9 ng/mL (n = 188) at week 24, 
-5.4 ng/mL (n = 189) at week 36, and -3.3 ng/mL (n = 243) 
at week 52.
In pooled short-term studies with active comparator 
controls, the median endpoint change was highest in the 
haloperidol group (+8.5 ng/mL), then in the olanzapine and 
lurasidone group (+3.4 ng/dL and +1.1 ng/dL) compared 
with the placebo group (+0.5 ng/mL).16
In a long-term safety trial, the median changes from 
baseline in prolactin levels significantly favored lurasidone-
treated patients compared with the risperidone group (+0.10 
[n = 378] versus +9.10 [n = 176] ng/mL at month 12, 
P = 0.001).33,34
Cardiovascular side effects
In the short-term lurasidone trials, there have been no reports 
of increased QTc . 500 msec and no cases observed with 
electrocardiographic abnormalites.16,17 Mean QTc change 
was +1.5 msec (n = 972) for lurasidone, -2.8 msec (n = 67) 
for haloperidol, +4.1 msec (n = 121) for olanzapine, and 
+1.9 msec (n = 436) for placebo. Comparison of lurasidone 
and ziprasidone over a three-week period found no clinically 
significant elevations in QTc, although lurasidone treat-
ment was associated with a lower endpoint change in QTc 
(+0.3 msec versus +3.3 msec).28Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The low affinity for α1-adrenergic receptors should ensure 
a low risk of orthostatic hypotension. The percentage of 
patients with orthostatic hypotension from short-term trials 
was low (lurasidone 40 mg/day, 0.8%; lurasidone 80 mg/
day, 1.4%; lurasidone 120 mg/day, and 1.7%, and 0.9% 
with placebo).17
Summary of safety data
In summary, lurasidone is well tolerated, especially 
with regard to metabolic effects. Although results of the 
preclinical studies suggested that lurasidone had a low 
potential for causing clinically significant extrapyramidal 
symptoms, these were observed with a higher frequency 
than expected.
There were no signs of glucose elevation or lipid changes 
with lurasidone. There was a small increase in weight with 
lurasidone, presumably related to the low affinity for 5HT2C 
receptors and no affinity for histaminic H1 receptors. Like 
ziprasidone, but unlike olanzapine, risperidone, and quetiap-
ine, lurasidone has a neutral effect on weight and on glucose 
or lipid metabolism.
Lurasidone increases prolactin levels at the beginning 
of treatment. This increase appears to be dose-related and 
different in men and women. In no trials were there any clini-
cally relevant changes in vital signs and electrocardiographic 
recordings. However, most current data from short-term stud-
ies and several longer trials are in progress, with data not yet 
available. The results of these studies are awaited in order to 
assess the long-term safety profile of lurasidone.
Place of lurasidone in clinical  
practice
Lurasidone has been shown to be efficacious in the treatment 
of the acute phase of schizophrenia, and seems to be well 
tolerated. It is a further member of the array of chemical enti-
ties classified as second-generation antipsychotics recently 
adopted by the FDA for this indication.
Accordingly, it was of interest to determine the position of 
lurasidone with respect to the other second-generation antipsy-
chotics in practical clinical use. Because of the heterogeneity 
of this drug class, the choice of a second-generation antipsy-
chotic in practice is made according to its tolerability profile. 
Tolerability profiles of the different second-generation antip-
sychotics available are compared and presented in Table 5.36 
While the side effects of first-generation antipsychotics are 
dominated by extrapyramidal symptoms, second-generation 
antipsychotics are often associated with a risk of secondary 
metabolic effects (weight gain, diabetes, or dyslipidemia). 
Lurasidone, like other recent second-generation antipsychot-
ics (aripiprazole, asenapine, and ziprasidone), is distinguished 
by its good metabolic tolerability profile. Lurasidone does not 
appear to have any significant adverse impact on metabolic 
indices, unlike other second-generation antipsychotics such 
as olanzapine and clozapine, and, to a lesser extent, risperi-
done and quetiapine. Lurasidone is also associated with good 
cardiovascular tolerability, without hypertension or widening 
of QT interval, whatever the dosage used.
However, it has a significant impact, albeit moderate, 
on the occurrence of akathisia, extrapyramidal symptoms, 
Table 5 Adverse effects of lurasidone compared with those of other antipsychotics
Drug QT prolongation Hypotension Sedation Weight gain Metabolic  
syndrome
Extrapyramidal  
symptoms
Prolactin 
elevation
Lurasidone - - + +/- - + +/-*
Amisulpride + - - + + + +++
Aripiprazole - - - +/- +/- +/- -
Asenapine + - - +/- - +/- +/-
Chlorpromazine ++ +++ +++ ++ ++ ++ +++
Clozapine + +++ +++ +++ +++ - -
Haloperidol ++ + + + + +++ +++
Olanzapine + + ++ +++ +++ +/- +
Paliperidone + ++ + ++ ++ + +++
Quetiapine ++ ++ ++ ++ ++ - -
Risperidone + ++ + ++ ++ + +++
Sertindole +++ +++ - + + - +/-
Sulpiride + - - + + + +++
Ziprasidone +++ + + +/- +/- +/- +/-
Notes: *Short-term trials reported an increase and long-term safety study found no increase in prolactin levels. Adapted from The Maudsley Prescribing Guidelines 10th ed;36 
reproduced with permission from the publisher.
Abbreviations: +++, high incidence/severity; ++, moderate incidence/severity; +, low incidence/severity; -, very low incidence/severity. Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and hyperprolactinemia at the start of treatment. These side 
effects bring it closer to the first-generation antipsychotics, or 
risperidone and paliperidone, than to other second-generation 
antipsychotics. The use of lurasidone thus appears to be of 
particular interest in patients presenting with or vulnerable 
to endocrine (diabetes, dyslipidemia) or cardiovascular 
comorbidities, or who are overweight.
Continuous prophylactic antipsychotic treatment reduces 
the risk of relapse by approximately 70%.37 A trial has dem-
onstrated that even short medication gaps, including periods 
from 1–10 days, are associated with an increase in the risk 
of hospitalization.38 Noncompliance with antipsychotic 
medication is often considered to be the most important 
factor related to relapse. Treatment-related issues that may 
affect compliance are primarily related to the efficacy and 
tolerability of antipsychotics. In a post hoc analysis of a 
study conducted in Germany on a sample of schizophrenic 
patients, their compliance with antipsychotic medication was 
strongly associated with subjective well-being, and further 
factors were clinical symptoms and side effects.39
The overall tolerability profile of lurasidone compared 
with other second-generation antipsychotics appears to 
be compatible with good patient acceptability and good 
compliance. As with other recently commercialized second-
generation antipsychotics, it would be of interest to evaluate 
the efficacy of lurisadone in real-world conditions, by mea-
suring the time elapsed before cessation of treatment for 
whatever cause, as in the CUtLASS and CATIE trials. These 
studies demonstrated that patients treated with neuroleptics 
and second-generation antipsychotics had similar levels of 
compliance, with a high dropout rate, and that these findings 
might be due in part to the fact that second-generation agents 
induced another range of side effects, including weight gain, 
impaired glucose tolerance, and dyslipidemia.12,13 Once 
again, the favorable metabolic profile of lurasidone may 
be associated with a longer treatment time than with the 
other antipsychotics. However, it also seems necessary to 
evaluate akathisia in subjective well-being and its effect on 
patient compliance.
In addition to its affinity for D2 and 5-HT2A receptors, lur-
asidone has high affinity for 5HT7, 5HT1A, and α2C receptors 
that may be involved in the improvement of cognitive and 
thymic symptoms in schizophrenic patients. Only one trial 
evaluating the cognitive effect of lurasidone is available to 
date.24 As we have seen, it presents several methodological 
limitations and does not yield significant results. Likewise, 
we have limited information on the efficacy of lurasidone 
for depressive symptoms in schizophrenic patients.31 If firm 
evidence were found for improved cognitive dysfunction 
or depressive symptoms in patients, then lurasidone would 
stand out among the other second-generation antipsychotics 
for efficacy.
In summary, lurasidone offers several advantages over 
other second-generation antipsychotics, ie, simple practical 
use (daily dose, administration possible with food), early 
efficacy, and good tolerability, in particular cardiometabolic. 
This new tolerability profile further extends the heterogeneity 
of the class of second-generation antipsychotics, and supports 
the view of some authors that this classification needs to be 
reviewed.40 Other therapeutic perspectives for lurasidone are 
being evaluated, in particular for bipolar depression with the 
ongoing PREVAIL 1, 2, 3 (PRogram to Evaluate Antidepres-
sant Impact of Lurasidone) and maintenance trials, designed 
to assess the efficacy of lurasidone as monotherapy, addon 
therapy, and prophylaxis for this indication.
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